Tracon Pharmaceuticals, Inc. 4
4 · Tracon Pharmaceuticals, Inc. · Filed Feb 5, 2015
Insider Transaction Report
Form 4
DRANT RYAN D
10% Owner
Transactions
- Conversion
Common Stock
2015-02-04+1,388,474→ 1,388,474 total(indirect: See Note 2) - Conversion
Series B Redeemable Convertible Preferred Stock
2015-02-04−5,373,396→ 0 total(indirect: See Note 2)→ Common Stock (1,388,474 underlying) - Purchase
Common Stock
2015-02-04$10.00/sh+500,000$5,000,000→ 1,888,474 total(indirect: See Note 2)
Footnotes (3)
- [F1]In connection with the Issuer's initial public offering on February 4, 2015, the shares of Series B Redeemable Convertible Preferred Stock automatically converted into the Issuer's common stock at a rate of 1 share of common stock for each 3.87 shares of Preferred Stock for no additional consideration. The Series B Redeemable Convertible Preferred Stock had no expiration date.
- [F2]The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
- [F3]NEA 14 purchased these shares directly from the Issuer in a private placement.